Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Scancell founder says the company is ready to commercialise novel medicines to counteract cancer

Scancell founder says the company is ready to commercialise novel medicines to counteract cancer

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.25
Bid: 9.50
Ask: 11.00
Change: 0.50 (5.13%)
Spread: 1.50 (15.789%)
Open: 9.75
High: 10.25
Low: 9.75
Prev. Close: 9.75
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Aptamer reshuffles board; Scancell expands trial

Mon, 31st Jul 2023 10:46

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Scancell Holdings PLC, up 25% at 11.52 pence, 12-month range 8.65p-29.40p. The cancer immunotherapies developer says it has expanded its Modi-1 trial for the use of checkpoint inhibitors on cancer patients. Scancell says the safety review committee has approved the addition of two new cohorts of 21 patients each. This move follows the successful completion of cohort four of the trial, which showed that patients with renal, head and neck cancer who received at least two doses of Modi-1 combined with CPI tolerated the treatment well, with no safety concerns.

----------

Tertiary Minerals PLC, up 12% at 0.10p, 12-month range 0.083p-0.31p. The mineral exploration and development company says it has received permission from the Forest Department of Zambia to carry out soil sampling in forested areas at its Mukai and Mushima North project licenses. The firm says it is exploring the two license areas for copper, with two targets, C1 and A1, identified at Mushima. Chair Patrick Cheetham says: "Our objective is to now complete soil sampling over the exciting targets we have developed at Mushima North and Mukai as well as at our Konkola West Project. This will enable us to prioritise our Zambian Projects for follow up drilling having already completed similar programmes at our Lubuila and Jacks Projects."

----------

AIM - LOSERS

----------

Aptamer Group PLC, down 45% at 2.64p, 12-month range 2.00p-100.00p. The provider of Optimer binders for use in therapeutics, diagnostics, bioprocessing and research says it has terminated its sale process after announcing it had conditionally completed a fundraise. The company says it conditionally raised GBP3.6 million, and accordingly the board decided to terminate the formal sale process. "The company is not in discussions with any party in relation to a sale and is not in receipt of any approaches," says Aptamer. The company also reveals that Chair Ian Gilham and Interim Chief Executive Officer & Chief Financial Officer Rob Quinn have resigned, effective from August 21. The company announced that it had appointed Steve Hull as chair from the same date, and promoted Andrew Rapson, current head of finance, to CFO.

----------

Jadestone Energy PLC, down 32% at 23.70p, 12-month range 23.00p-103.00p. The oil and gas production company focused on the Asia-Pacific region says production is temporarily shut at Montara floating production storage and offloading facility offshore Australia due to a gas alarm in tank 4S. It says the tank will be emptied, cleaned and inspected over the next few weeks. Production at Montara had only resumed in March after closing down in August of last year for repair activities. Chief Executive Officer Paul Blakeley says: "While disappointing and frustrating to have to shut in Montara again, we will find and repair any additional defect while continuing with the overall planned programme of inspection of the storage tanks on the FPSO. The safety of our personnel, as well as the long-term integrity of the asset, are paramount. We will provide a further update once the inspection of tank 4S is complete."

----------

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
31 Aug 2016 11:37

Hygea VCT Net Asset Value Drops In Half-Year As Scancell Shares Slide

Read more
21 Jul 2016 08:32

Scancell Signs SCIB1 Vaccine Manufacturing Deal With Eurogentec

Read more
20 Jul 2016 12:35

Scancell granted product licence extension from Ichor Medical Systems

(ShareCast News) - Scancell, the developer of immunotherapies for cancer treatments, was granted a product licence option extension from Ichor Medical Systems. The extension is to licence the commercial use of Ichor's TriGrid electroporation delivery system with SCIB1, Scancell's ImmunoBody vaccine,

Read more
20 Jul 2016 08:30

Scancell Licence To Use TriGrid Technology Extended To 2018 (ALLISS)

Read more
13 Jul 2016 09:19

Scancell Says Review Supporting Potential Of Moditope Published

Read more
6 Jul 2016 08:28

Scancell Holdings SCIB1 Cancer Drug Shows "Compelling" Survival Data

Read more
17 Jun 2016 12:24

Scancell suspends dosing with current supplies of SCIB1 for melanoma

(ShareCast News) - Shares in drug developer Scancell Holdings plunged almost 17% after it suspending dosing with current clinical trial supplies of SCIB1 for melanoma with immediate effect. Patients would be notified as soon as possible. AIM-quoted Scancell said quality-control analysis showed the

Read more
17 Jun 2016 09:46

WINNERS & LOSERS SUMMARY: National Grid Hit By Break-Up Recommendation

Read more
17 Jun 2016 08:10

UPDATE 1-Scancell slumps as drug problem disrupts melanoma trial

(Adds latest shares, details) LONDON, June 17 (Reuters) - British drug developer Scancell has suspended dosing in a cancer clinical trial because of quality problems with an immunotherapy treatment, wiping more than a quarter off the value of its shares on Friday. The company said te

Read more
17 Jun 2016 07:46

BUZZ-Scancell: drug problem spurs worst day in 3 yrs

** Drug developer Scancell's shares down 27 pct, worst day in nearly three years, after suspends dosing in a cancer clinical trial because of quality problems with its immunotherapy treatment SCIB1 ** Co says current supplies of drug no longer meet original specification and are no longer s

Read more
17 Jun 2016 06:51

Drug problem forces Scancell to suspend cancer trial dosing

LONDON, June 17 (Reuters) - British drug developer Scancell said on Friday it was suspending dosing in a cancer clinical trial because of quality problems with its immunotherapy treatment SCIB1. The company said tests showed the product, which is being assessed for melanoma, was "no longer

Read more
17 Jun 2016 06:44

Scancell Holdings Suspends Dosing In SCIB1 Cancer Treatment Trials

Read more
2 Jun 2016 07:57

Scancell's ImmunoBody Platform Chosen For Preclinical Glioma Study

Read more
19 May 2016 05:55

CORRECT (18/05): Scancell Shuffles Board As New US Offices Open

Read more
18 May 2016 08:31

BROKER RATINGS SUMMARY: Goldman Upgrades Booker, Panmure Cuts Meggitt

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.